DATA TRANSMITTAL DOCUMENT

1. Name and Address of Submitter

Sharda USA LLC c/o Wagner Regulatory Associates P.O. Box 640, 7217 Lancaster Pike, Suite A Hockessin, DE 19707 EPA Company No. 83529

2. Regulatory Action In Support Of Which This Package Is Submitted

Application for Registration

Sharda Prothioconazole 19% + Tebuconazole 19% SC, ABN: TAJ, ABN: Ellora

3. <u>Transmittal Date</u>

January 20, 2021

4. <u>List of Submitted Studies</u>

51429201	Sharda Prothioconazole 19% + Tebuconazole 19% SC Product Identity and Composition, Description of Materials, Description of the Formulation Process, Discussion of Formation of Impurities, Preliminary Analysis and Certified Limits, OPPTS: 830.1550, 830.1600, 830.1650, 830.1670, 830.1700, 830.1750		
51429202	Determination of Active Ingredient Content of Prothioconazole 19% + Tebuconazole 19% SC, Study No. 20603, OPPTS: 830.1800		
51429203	Determination of Accelerated Storage Stability of Prothioconazole 19% + Tebuconazole 19% SC, Study No. 20604, OPPTS: 830.6302, 830.6303, 830.6304, 830.6314, 830.6315, 830.6316, 830.6317, 830.6320, 830.7000, 830.7100, 830.7300		
51429204	Sharda Prothioconazole 19% + Tebuconazole 19% SC Product Chemistry – Group B: Request for Waiver for Certain Physical / Chemical Properties Data, OPPTS: 830.6313, 830.6319, 830.6321, 830.7050, 830.7200, 830.7220, 830.7370, 830.7520, 830.7550, 830.7560, 830.7570, 830.7840, 860.7860, 830.7950		
51429205	Acute Oral Toxicity Study with Prothioconazole 19% + Tebuconazole 19% SC in Wistar Rats, Study No. 20543, OPPTS: 870.1100		
51429206	Acute Dermal Toxicity Study (Fixed Dose Procedure) with Prothioconazole 19% + Tebuconazole 19% SC in Wistar Rats, Study No. 20544, OPPTS: 870.1200		
51429207	Acute Inhalation Toxicity Study with Prothioconazole 19% + Tebuconazole 19% SC in Wistar Rats, Study No. 20548, OPPTS: 870.1300		
51429208	Acute Eye Irritation /Corrosion Study with Prothioconazole 19% + Tebuconazole 190% SC in New Zealand White Rabbits, Study No. 20546, OPPTS: 870.2400		
51429209	Acute Dermal Irritation/Corrosion Study with Prothioconazole 19% + Tebuconazole 19% SC in New Zealand White Rabbits, Study No. 20545, OPPTS: 870.2500		
51429210	Skin Sensitization Potential of Prothioconazole 19% + Tebuconazole 19% SC in Guinea Pigs (Guinea Pig Maximization Test of Magnusson and Kligman method), Study No. 20547, OPPTS: 870.2600		
Company	y Name:	Sharda USA LLC	
Company	y Official:	Keeva Shultz	Keeva Shultz Signature
		Authorized Agent	Signature
Company	y Contact:	Keeva Shultz	(302) 635-7281 / keeva@wagnerreg.com
		Authorized Agent	Phone / Email